← All trials
NCT00428727
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2005
- Primary completion
- Feb 1, 2011
- Completion date
- Feb 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fundación Cardiovascular de ColombiaLead sponsor
- Fundación Cardiovascular de ColombiaOverall official - principal investigator
- University of AkronOverall official - principal investigator
- Fundación Cardiovascular de ColombiaStudy chair
- Fundación Santandereana de Diabetes y ObesidadStudy chair
- Instituto de Seguros SocialesStudy chair
- University of AkronStudy chair
- Universidad de SantanderCollaborator
- Instituto de Salud de BucaramangaCollaborator
- University of AkronCollaborator
- Fundación Santandereana de Diabetes y ObesidadCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.